ArticleProceedings of the National Academy of Sciences of the United States of America2019
Addressing cellular heterogeneity in tumor and circulation for refined prognostication.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Standard deviation of CT radiomic features among malignancies in each individual: prognostic ability in lung cancer patients.Journal of cancer research and clinical oncology · 2023Trial
- Decoding Cellular Heterogeneity with Microfluidic Single-Cell Secretion Analysis Tools.ACS omega · 2026Review
- Genetic and phenotypic profiling of single living circulating tumor cells from patients with microfluidics.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Suppression of ZNF205-AS1/EGR4 positive feedback loop attenuates cisplatin resistance of non-small cell lung cancer cells via targeting miR-138-5p/OCT4 pathway.Journal of thoracic disease · 2024Article
- Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI).NPJ precision oncology · 2023Article
- Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity.Journal of experimental & clinical cancer research : CR · 2023Article
- Sequence-Based Platforms for Discovering Biomarkers in Liquid Biopsy of Non-Small-Cell Lung Cancer.Cancers · 2023Review
- High Platelet Count is a Potential Prognostic Factor of the Early Recurrence of Hepatocellular Carcinoma in the Presence of Circulating Tumor Cells.Journal of hepatocellular carcinoma · 2023Article
- CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity.Heliyon · 2023Article
- Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA.Therapeutic advances in medical oncology · 2023Review
- Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer.Frontiers in oncology · 2023Article
- Transcriptional Heterogeneity of Cellular Senescence in Cancer.Molecules and cells · 2022Review
- N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor.Journal for immunotherapy of cancer · 2022Article
- Functional Tumor Targeting Nano-Systems for Reprogramming Circulating Tumor Cells with In Situ Evaluation on Therapeutic Efficiency at the Single-Cell Level.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- [Recent advances in isolation and detection of circulating tumor cells with a microfluidic system].Se pu = Chinese journal of chromatography · 2022Review
- Article
- Application of Microfluidics in Detection of Circulating Tumor Cells.Frontiers in bioengineering and biotechnology · 2022Review
- Article
- Article
- Progress and application of circulating tumor cells in non-small cell lung cancer.Molecular therapy oncolytics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite pronounced genomic and transcriptomic heterogeneity in non-small-cell lung cancer (NSCLC) not only between tumors, but also within a tumor, validation of clinically relevant gene signatures for prognostication has relied upon single-tissue samples, including 2 commercially available multigene tests (MGTs). Here we report an unanticipated impact of intratumor heterogeneity (ITH) on risk prediction of recurrence in NSCLC, underscoring the need for a better genomic strategy to refine prognostication. By leveraging label-free, inertial-focusing microfluidic approaches in retrieving circulating tumor cells (CTCs) at single-cell resolution, we further identified specific gene signatures with distinct expression profiles in CTCs from patients with differing metastatic potential. Notably, a refined prognostic risk model that reconciles the level of ITH and CTC-derived gene expression data outperformed the initial classifier in predicting recurrence-free survival (RFS). We propose tailored approaches to providing reliable risk estimates while accounting for ITH-driven variance in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.